Claret Asset Management’s ProMIS Neurosciences PMN Stock Holding History

Claret Asset Management’s Portfolio PMN Stock Details PMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-453	Closed	-$5K	–	408
2025 Q3	$5K	Hold	453	–	–	﹤0.01%	407
2025 Q2	$5K	Buy	+453	New	+$6.18K	﹤0.01%	436
2025 Q1	–	Sell	-453	Closed	-$9.62K	–	302
2024 Q4	$11K	Hold	453	–	–	﹤0.01%	306
2024 Q3	$14K	Buy	453 +20	+5%	+$747	﹤0.01%	335
2024 Q2	$16K	Hold	433	–	–	﹤0.01%	251
2024 Q1	$21K	Hold	433	–	–	﹤0.01%	212
2023 Q4	$12K	Hold	433	–	–	﹤0.01%	191
2023 Q3	$22K	Sell	433 -60	-12%	-$3.9K	﹤0.01%	156
2023 Q2	$47K	Hold	493	–	–	0.01%	156
2023 Q1	$59K	Hold	493	–	–	0.01%	152
2022 Q4	$55K	Hold	493	–	–	0.01%	147
2022 Q3	$75K	Buy	+493	New	+$72.6K	0.02%	146

Other funds holding PMN

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

DEM

Disciplined Equity Management Neptune Beach, Florida $226M AUM 27.21% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Claret Asset Management's PMN Position: Q4 2025 in Review

Claret Asset Management sold out of ProMIS Neurosciences (PMN) in Q4 2025, closing a stake of 453 shares — an estimated $5K sold.

Claret Asset Management first reported a position in PMN in Q3 2022 and held it in 12 quarters. The position peaked at $75K in Q3 2022. 9 funds tracked by Wall St. Rank hold PMN as of Q4 2025.

Claret Asset Management reported no remaining ProMIS Neurosciences position as of Q4 2025 after selling out during the quarter.
Claret Asset Management sold 453 ProMIS Neurosciences shares in Q4 2025, an estimated $5K.
Claret Asset Management first reported a position in ProMIS Neurosciences in Q3 2022 and held it in 12 quarters.
Claret Asset Management's ProMIS Neurosciences position peaked at $75K in Q3 2022.
9 funds tracked by Wall St. Rank held ProMIS Neurosciences as of Q4 2025.

Based on Claret Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.